Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other rare and metabolic indications. The company is headquartered in London, the United Kingdom.
| Revenue (TTM) | 839,000 |
| Gross Profit (TTM) | 667,000 |
| EBITDA | $-71.08M |
| Operating Margin | -3565.00% |
| Return on Equity | -92.60% |
| Return on Assets | -29.80% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $1.05 |
| Price-to-Book | 9.98 |
| Price-to-Sales (TTM) | 571.43 |
| EV/Revenue | 169.98 |
| EV/EBITDA | -5.78 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 197.20% |
| Shares Outstanding | $47.23M |
| Float | $25.92M |
| % Insiders | 24.63% |
| % Institutions | 44.57% |
Volatility is currently expanding
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Silence Therapeutics Plc (NASDAQ:SLN) shares are up during Friday's session. On Thursday, the company highlighted follow-up data from its Phase 1 SANRECO study of divesiran.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2026 Annual Congress. Divesiran data presented at EHA show improvem.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET. A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be avail.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archiv.
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
